| Identification | Back Directory | [Name]
RUFLOXACIN | [CAS]
101363-10-4 | [Synonyms]
Qari
Mones
Tebraxin
ISF-09334
RUFLOXACIN
4]thiazino[2
AKOS NCG1-0068
3-dihydro-7H-[1
RUFLOXACIN USP/EP/BP
4-ij]quinoline-6-carboxylic acid
9-Fluoro-10-(4-methylpiperazin-1-yl)-7-oxo-2
8-FLUORO-9-(4-METHYL-PIPERAZIN-1-YL)-6-OXO-2,3-DIHYDRO-6H-1-THIA-3A-AZA-PHENALENE-5-CARBOXYLIC ACID
9-Fluom-2，3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1，2，3-de]-1，4-benzothiazine-6-carboxylic acid
9-Fluoro-2,3-dihydro-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid
7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- | [Molecular Formula]
C17H18FN3O3S | [MDL Number]
MFCD00865073 | [MOL File]
101363-10-4.mol | [Molecular Weight]
363.41 |
| Hazard Information | Back Directory | [Definition]
ChEBI: Rufloxacin is a member of quinolines, a quinolone antibiotic and a fluoroquinolone antibiotic. | [Pharmaceutical Applications]
A tricyclic fluoroquinolone formulated as the hydrochloride salt. It is inactive against Gram-positive cocci with MICs >2 mg/L. It displays weak activity in vitro against Enterobacteriaceae with the MIC for most species >1 mg/L. Activity against Ps. aeruginosa is poor (MIC 16–32 mg/L). After loading doses of 400 and 600 mg followed with 9 days of either 200 or 300 mg, mean peak plasma levels were around 4.5–7 mg/L, respectively. The mean apparent elimination halflife was 44 h. Approximately 50% is eliminated in the urine.
It has been used in urinary tract infection and chronic prostatitis, but clinical experience is limited. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|